Methotrexate in compassionate use improved acute pneumonia and myocarditis in a patient with COVID-19

Authors

  • Nery E. Linarez Hospital General del Sur
  • Francisco Lavadie Rivas Hospital General del Sur
  • Irma Reyes Hospital General del Sur
  • Reyna M. Durón Universidad Tecnológica Centroamericana (UNITEC)
  • Gaspar Rodríguez Consorcio de Investigadores COVID Honduras

DOI:

https://doi.org/10.5377/innovare.v10i3.12981

Abstract

Chest CT scan of a 26-year-old Honduran male with COVID-19 and moderate pneumonia (A, arrows). Due to tocilizumab shortage, compassionate use of methotrexate (MTX) was done in a single 25mg IV dose by day 11 of disease, under monitoring by an ad-hoc ethics commission. Two weeks after initial clinical improvement, he developed acute myocarditis with atrioventricular block (B). Remission occurred after a second dose of the drug (C, D). MTX is well known by its use in several oncological and autoimmune conditions, and by its potential in reducing phosphorylation of JAK1/STAT3 and IL6 expression. Several reports suggest that MTX could be repurposed as therapy for the cytokine storm due to SARS-CoV-2

Downloads

Download data is not yet available.
Abstract
571
Methotrexate in compassionate use improved acute pneumonia and myocarditis in a patient with COVID-19 145

Downloads

Published

2021-12-15

How to Cite

Linarez, N. E., Lavadie Rivas, F. ., Reyes, I. ., Durón, R. M. ., & Rodríguez, G. (2021). Methotrexate in compassionate use improved acute pneumonia and myocarditis in a patient with COVID-19 . Innovare: Revista De Ciencia Y tecnología, 10(3), 138. https://doi.org/10.5377/innovare.v10i3.12981

Issue

Vol. 10 No. 3 (2021)

Section

Image

License

Copyright (c) 2021 Nery E. Linarez, Francisco Lavadie Rivas, Irma Reyes, Reyna M. Durón

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.